NOVYY REZhIM PERVOY LINII KhIMIOTERAPII METASTATIChESKOGO KOLOREKTAL'NOGO RAKA
- Autores: Darenskaya A.D1, Dobrova N.V1
-
Afiliações:
- Edição: Nº 8 (2014)
- Páginas: 57-61
- Seção: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/286936
- ID: 286936
Citar
Texto integral
Acesso aberto
Acesso está concedido
Acesso é pago ou somente para assinantes
Resumo
The article presents the intermediate results of the evaluation of newly developed regimen of 1st line chemotherapy of metastatic colorectal cancer, including oxaliplati, irinotecan, and 5-fluorouracil in the weekly and extended mode ± panitumumab. This mode of chemotherapy has demonstrated high efficacy and low toxicity. Objective tumor response to the treatment was registered in 100 % of cases. A clinical case of the application of the three-component chemotherapy regimen for the achievement of complete tumor regression in a patient with metastatic colorectal cancer is demonstrated.
Palavras-chave
Texto integral
Bibliografia
- Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J. Clin. 2010; 60: 277-300.
- Чиссов В.И., Старинский В.В., Петрова Г.В. Состояние онкологической помощи населению России в 2012 г. М., 2013.
- Falcone A., Ricci S., Brunetti I., et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J. Clin. Oncol. 2007; 25(13): 1670-76.
- Masi G., Vasile E., Loupakis F., et al. Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis. J. Natl. Cancer Inst. 2011; 103(1): 21-30.
- Peinert S., Grothe W., Stein A., et al. Safety and efficacy of weekly 5-fluorouracil/folinic acid/ oxaliplatin/irinotecan in the first-line treatment of gastrointestinal cancer. Ther. Adv. Med. Oncol. 2010; 2 (3): 161-74.
- Vasile E., Masi G., Fornaro L., et al. A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer. Br. J. Cancer. 2009; 100(11): 1720-24.
- Bajetta E., Celio L., Ferrario E., et al. Capecitabine plus oxaliplatin and irinotecan regimen every other week: a phase I/II study in first-line treatment of metastatic colorectal cancer. Ann. Oncol. 2007; 18(11): 1810-16.
Arquivos suplementares
